Targeting harmful protein structures in Alzheimer's disease
Chemical approaches to selectively target beta-rich amyloids
This study is looking for new ways to create special tools that can target and break apart the harmful proteins linked to Alzheimer's disease, with the hope of finding better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-11090420 on NIH RePORTER |
What this research studies
This research focuses on developing chemical probes that can selectively target and disrupt beta-rich amyloid structures associated with Alzheimer's disease. By understanding how these proteins interact and aggregate, the researchers aim to create innovative compounds that can stabilize or inhibit the formation of toxic amyloid fibrils. The approach involves using advanced techniques to mimic and disrupt the interactions of these harmful proteins, potentially leading to new therapeutic options for patients. The research utilizes patient-derived samples to ensure relevance and applicability to real-world conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline related to amyloid accumulation.
Not a fit: Patients with non-Alzheimer's forms of dementia or cognitive impairment unrelated to amyloid pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in targeting amyloid structures, indicating that this approach could lead to significant advancements in Alzheimer's treatment.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Del Valle, Juan R — University of Notre Dame
- Study coordinator: Del Valle, Juan R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.